Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Authentic Urban areas: Rich Legacy and Lively Societies - 2Israel explores creation of int'l force with Greece, Cyprus to deter Turkey
- 3Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- 4Virtual National Science Foundation internships aren’t just a pandemic stopgap – they can open up opportunities for more STEM students
- 5Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- BHP liable for 2015 Brazil mine disaster: UK court
- Change Your Physical make-up: Compelling Activities for Muscle Building
- Instructions to Plan for Your Teeth Substitution Methodology
- Putin, Netanyahu discuss Middle East in phone call, Kremlin says
- Tehran defends ship seizure as a legal action, but tensions continue in the Gulf
- The Manual for Electric Vehicles that will be hot merchants in 2023
- Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico
- Figure out How to Consolidate Cutting edge innovations in Senior's SUVs
